There was no significant difference in survival outcomes with trabectedin or physician’s choice of chemotherapy.
Researchers described distinct anxiety profiles and identified clinical characteristics of each one.
Mirvetuximab soravtansine is an antibody-drug conjugate comprised of a FRα-binding antibody, a cleavable linker, and a potent tubulin-targeting agent.
The risk of dying from a subsequent primary cancer remained significantly elevated for 20 years or more for some patients.
A meta-analysis sought to determine the rates of late-stage presentation among women with cervical cancer.